Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development-Reference-Cited by-同舟云学术

Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development

Published:2007-07-01 Issue:7 Volume:12 Page:840-849
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Gridelli Cesare¹,Bareschino Maria Anna²,Schettino Clorinda²,Rossi Antonio¹,Maione Paolo¹,Ciardiello Fortunato²

Affiliation:

1. a Division of Medical Oncology, “S.G. Moscati” Hospital, Avellino, Italy

2. b Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery “F. Magrassi and A. Lanzara,” Second University of Naples, School of Medicine, Naples, Italy

Abstract

Learning Objectives After completing this course, the reader will be able to: Describe the molecular mechanism of action of erlotinib.Define clinical and molecular predictors of response to erlotinib.Describe the clinical trials performed with erlotinib in NSCLC and underline future clinical development of this drug in the treatment of NSCLC. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.12-7-840

Reference56 articles.

1. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results;Breathnach;J Clin Oncol,2001

2. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

3. Target-based agents against ErbB receptors and their ligands: A novel approach to cancer treatment;Normanno;Endocr Relat Cancer,2003

4. Blockade of receptors for growth factor: An anticancer therapy – the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture;Mendelsohn;Clin Cancer Res,2000

5. The ErbB signaling network: Receptor heterodimerization in development and cancer;Olayioye;EMBO J,2000

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ultra‐high‐performance liquid chromatography–quadrupole time of flight tandem mass spectrometry based in vitro metabolite profiling of DK‐GV‐04P, a novel anticancer molecule under drug discovery;Biomedical Chromatography;2023-12-12

2. A Series of Composited Tumor DNA Reference Materials Containing Three Genes and Ten Mutation Positions for CNV and SNV Detection;2023-05-05

3. Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer;ESMO Open;2023-04

4. The Concept of Cancer Translational Research - A Review;Journal of Population Therapeutics and Clinical Pharmacology;2023-01-01

5. ANALYTICAL METHOD VALIDATION AND BIOEQUIVALENCE STUDY OF ERLOTINIB 150 MG TABLETS IN IRANIAN HEALTHY VOLUNTEERS UNDER FASTING CONDITION;International Journal of Pharmacy and Pharmaceutical Sciences;2023-01-01